Cabaletta Bio, Inc.
HealthcareNASDAQ:CABA · NASDAQ Global Select
+$0.00 today
Vol 2.89M · Avg 3.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-149.8%
avg -19.2%
ROIC
-123.8%
avg -31.0%
ROA
-101.7%
avg -2816.6%
Analysis
ROA is currently the strongest return metric at -101.7% versus its period average of -2816.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Steven A. Nichtberger | Co-Founder, Chairman, Chief Executive Officer & President | $1.13M | — | 65 | $674,000.00 | 0.41% |
David J. Chang FACR | Chief Medical Officer | $807,135.00 | — | 63 | $225,000.00 | 0.14% |
Gwendolyn K. Binder | President of Science & Technology | $773,962.00 | — | 51 | $225,000.00 | 0.14% |
Anup Marda | Chief Financial Officer | $548,197.00 | — | 48 | $225,000.00 | 0.14% |
Aimee Payne | Co-Founder & Co-Chair of Scientific Advisory Board | — | — | — | — | — |
Michael C. Milone | Co-Founder & Co-Chair of Scientific Advisory Board | — | — | — | $22,000.00 | 0.01% |
Qing Sarah Yuan | Chief Technology Officer | — | — | 55 | — | — |
Samik Basu | Chief Scientific Officer | — | — | — | — | — |
Michael Gerard | General Counsel & Secretary | — | — | 46 | $175,000.00 | 0.11% |
Heather Harte-Hall | Chief Compliance Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$296,188.53
Sells
0
$0.00
Net Sentiment
+$296,188.53
Net buying
Most Active
Chang David J.
1 transactions
Analysis
Insiders reported 8 buys worth $296,188.53 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $296,188.53. Chang David J. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
Immutep Limited
NASDAQ:IMMP
$53.60M
Who manages CABA?
Cabaletta Bio, Inc. (CABA) lists 10 active executives. The top listed executive is Aimee Payne, Co-Founder & Co-Chair of Scientific Advisory Board.
Are CABA insiders buying or selling?
Recent insider activity shows net selling of $19.54M.
Explore More
Continue the stock analysis
Jump to another research area for this company.